The cardiovascular market outlook to 2016

709 views

Published on

This report gives an overview of the cardiovascular market, including analyses of the disease subcategories, market sizing, market forecasts, and growth drivers.

Published in: Business, News & Politics
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
709
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

The cardiovascular market outlook to 2016

  1. 1. The Cardiovascular Market Outlook to 2016Published:June 2011No.Of Pages:160Price:US $ 3835IntroductionThe large number of impending patent expirations of blockbuster drugs willnegatively impact the cardiovascular pharmaceutical segment. Evolving strategiesin this segment such as in-licensing of drug candidates, and marketing ofauthorized generics, along with the development of first-in-line novel therapeuticsmight offset the effects of genericization.Features and benefits* Gain an overview of the cardiovascular market, including analyses of the diseasesubcategories, market sizing, market forecasts, and growth drivers.* Develop insights into the R&D pipeline of leading pharmaceutical companies, andcompare the prospects for individual pipeline drugs.* Assess the innovative first-in-class drugs in the various therapeuticsubcategories, and judge their future market potential.* Reviewthe marketed product portfolio of the key players in this segment, andgain insights into the strategies that fuel their growth.* Examine the epidemiology of major cardiovascular indications, and assess themajor risk factors and prevalence forecasts to 2016.HighlightsCardiovascular diseases encompass a range of ailments such as hypertension,dyslipidemia, stroke, atherosclerosis, thrombosis, and coronary artery disease.Dyslipidemia was the indication with the highest reported prevalence in 2010 withan estimated 336 million cases in the seven major markets.Antidyslipidemic drugs occupied 18% of the cardiovascular segment in 2010. Theentry of Lipitor generics in 2011 is expected to negatively impact future prospectsof sales in this segment. Dalcetrapib, a CETP inhibitor, manufactured by Roche, is apotential blockbuster in this segment that could offset the negative impact ofgenericization.Antithrombotics recorded strong sales in 2010, and occupied a market share of11%. This segment is forecast to deliver strong growth in the next two years owingto the commercialization of recently approved products such as Pradaxa and Xareltoand the expected launch of Pfizer/BMS’s apixaban in the US.
  2. 2. Browse All Pharmaceuticals Market Research ReportsYour key questions answered* What are the key growth drivers and resistors that will affect various therapeuticsub-categories of the cardiovascular market?* What are the novel therapeutics being developed in the cardiovascular segment,and which of these offer significant potential for future growth?* What are the various R&D strategies of top pharmaceutical companies, and howdo these strategies help in cost containment and sustenance of growth?* What are the key brands in the various therapeutic subcategories, and which ofthese are likely to enjoy significant growth in future?* How have the leading players built a strong position in the cardiovascularsegment and what are their growth strategies?Table Of ContentsExecutive SummaryOverview and epidemiology of cardiovascular disordersGlobal market analysisPipeline analysisCompetitive landscapeAbout Business InsightsDisclaimerOverview and epidemiology of cardiovascular disordersSummaryIntroductionRisk factorsPredisposing risk factorsModifiable risk factorsHypertensionDiagnosis, treatment and managementEpidemiologyForecast epidemiologyDyslipidemiaDiagnosis, treatment, and managementEpidemiologyForecast epidemiologyCardiovascular diseasesArteriosclerosis/atherosclerosisThrombosisCardiac arrhythmiasMyocardial infarction (MI)
  3. 3. Acute coronary syndrome (ACS)Congestive heart failure (CHF)Coronary artery disease (CAD)Peripheral artery disease (PAD)Pulmonary hypertensionAngina pectorisStrokeEpidemiologyForecast epidemiologyGlobal market analysisSummaryIntroductionMarket analysis by geographyKey events in the cardiovascular marketEuropean approval for RasilamloBMS/Pfizer’s apixaban likely to receive EU approvalAngiotensin receptor blockers (ARBs) may cause increased cancer riskCrestor’s patent upheld in the USPlavix boxed warning for poor metabolizersMarket analysis by drug classAntihypertensivesIntroductionAntihypertensive drug classesLeading treatment brands by drug classKey brands analysisAntidyslipidemicsIntroductionAntidyslipidemic drug classesLeading treatment brands by drug classKey brands analysisFuture blockbusters in the antidyslipidemic drug classAntithromboticsIntroductionAntithrombotics drug classesLeading treatment brands by drug classKey brands analysisFuture blockbusters in the antithrombotic drug classOther cardiovascular agentsIntroductionLeading treatment brands by drug classTracleerLeading brands dynamics and sales forecastsProduct growth-share matrix for leading brandsPipeline analysisSummary
  4. 4. IntroductionKey events in the cardiovascular marketFirst advanced therapy certificate for t2cure’s somatic cell therapyClear evidence of safety leads to termination of apixaban’s Phase III AVERROEStrialFDA panel to review AstraZeneca’s BrilintaNovartis presents successful Phase II results of LCZ696Daiichi Sankyo’s CS-8635 shows promising results in pivotal trialSanofi (Genzyme)/Isis’ mipomersen clears second Phase III trial, but raises safetyconcernsCardiovascular pipelineLeading drugs in developmentProfiles of key pipeline productsKey antihypertensive pipeline drugsKey antidyslipidemic pipeline drugsKey antithrombotic pipeline drugsCompetitive landscapeSummaryIntroductionCompetitive positioning of top players in the cardiovascular marketPfizerOverviewMarketed product portfolioR&D pipeline analysisStrategic and growth analysisSanofiOverviewMarketed product portfolioR&D pipeline analysisStrategic and growth analysisAstraZenecaOverviewMarketed product portfolioR&D pipeline analysisStrategic and growth analysisNovartisOverviewMarketed product portfolioR&D pipeline analysisStrategic and growth analysisBristol-Myers Squibb (BMS)OverviewMarketed product portfolioR&D pipeline analysisStrategic and growth analysisMerckOverview
  5. 5. Marketed product portfolioR&D pipeline analysisStrategic and growth analysisAppendixScope and methodologyScopeMethodologyAbbreviationsReferencesAbout Us:ReportsnReports is an online library of over 100,000+ market research reports andin-depth market research studies & analysis of over 5000 micro markets. Weprovide 24/7 online and offline support to our customers. Get in touch with us foryour needs of market research reports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page:http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog

×